MedTrace Logo

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

NCT01992861 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2023-06-26

No results posted yet for this study

Summary

This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. PET is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Comparing results of diagnostic procedures, such as MRI and PET, done before, during and after radiation and chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Conditions

  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Carcinoma
  • Cervical Squamous Cell Carcinoma, Not Otherwise Specified
  • Cervical Undifferentiated Carcinoma
  • Recurrent Cervical Carcinoma
  • Stage IB2 Cervical Cancer
  • Stage II Cervical Cancer
  • Stage IIA Cervical Cancer
  • Stage IIB Cervical Cancer
  • Stage III Cervical Cancer
  • Stage IIIA Cervical Cancer
  • Stage IIIB Cervical Cancer
  • Stage IVA Cervical Cancer

Interventions

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

PROCEDURE

Diffusion Weighted Imaging

Undergo DW MRI

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo DCE MRI

RADIATION

Fludeoxyglucose F-18

Undergo FDG PET/CT

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MR spectroscopy

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • Simon Lo · Fred Hutch/University of Washington Cancer Consortium

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-14
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United States
  • Canada
  • Hong Kong

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992861 on ClinicalTrials.gov